Apnimed Inc. raised $192 million in an initial public offering. The company is a late-stage drug developer focused on sleep apnea.
The IPO was priced at $16 per share. This price represented the top of the marketed range for the offering.
The transaction was an upsized US initial public offering. Apnimed Inc. is backed by Shionogi.